Continental AG Shares Jump After Q1 Profit Beats Expectations 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
LAKE FOREST, Ill., May 07, 2018 -- Depomed, Inc. (NASDAQ:DEPO) today announced that members of senior management will participate at the 2018 UBS Global Healthcare Conference in a session scheduled for 1:30 pm ET on Tuesday, May 22, 2018 in New York, NY.
This presentation will be webcast and can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcasts will be archived for 30 days.
About Depomed
Depomed is a leading specialty pharmaceutical company committed to putting the patient first in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain businesses and its emerging Orphan Specialty Business is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACTS:
John B. Thomas
SVP, Investor Relations and Corporate Communications
[email protected]
